Sprint Bioscience AB (publ) announces today that previously unpublished results from the company's VPS34 program will be presented at one of the world's largest conferences in cancer research, the American Association for Cancer Research (AACR) in New Orleans, Louisiana, USA, April 8-13, 2022.

The studies showed VPS34 inhibitor, SB02024, activated cGAS-STING signalling in human renal cancer cells, improved proinflammatory cytokine secretion in combination with STING agonist ADU-S100 in vitro and sensitized B16-F10 tumors to STING agonist treatment in an in vivo mouse model.

The results increase the understanding of the role of the autophagy kinase VPS34 in cancer cells’ ability to escape the immune system and for the potential of an immune-activating mechanism for the VPS34 program, which was licensed to Deciphera Pharmaceuticals in August 2021. Furthermore, the observations show that combinations between VPS34 inhibition and STING agonists have the potential to enable an enhancement of the treatment effect.

“The results increase the mechanistic understanding of VPS34 inhibition in cancer and we are pleased that these results are now presented to the leading researchers in the field and industry. With the presented findings, we have further support that inhibition of VPS34 warrants further development as a potential treatment alternative for patients with different types of cancer. We look forward to Deciphera Pharmaceuticals' development of the program ", says Martin Andersson, CSO at Sprint Bioscience.

The research presented at the AACR 2022 conference was conducted before the program was licensed to Deciphera Pharmaceuticals. Under the licensing agreement, Sprint Bioscience is eligible to receive up to an additional USD 273 million in potential development and commercial milestone payments, and in addition, sales-based royalties at levels ranging from mid-single to low double-digit percentages on sales of a potential product from the program.

The AACR Annual Meeting is one of the largest conferences in cancer research and attracts researchers from both academia and industry worldwide. The conference covers everything from basic research to clinical trials and many present previously completely unpublished information.

The poster “VPS34 inhibitor SB02024 activates cGAS-STING signaling and sensitizes tumors to STING agonist” is presented by Yasmin Yu, PhD, Senior Scientist, Sprint Bioscience, on site on April 11, 2022 between 1:30 PM and 5.00 PM. https://www.aacr.org/meeting/aacr-annual-meeting-2022/
https://www.abstractsonline.com/pp8/#!/10517/presentation/14050

For further information, kindly contact:

Erik Kinnman, CEO, Sprint Bioscience
Tel: 08-411 44 55
E-mail: erik.kinnman@sprintbioscience.com

About Sprint Bioscience AB (publ)

Sprint Bioscience develops small-molecule first-in-class drug projects with a focus on oncology. Using fragment-based drug discovery, the company develops drug programs in a time- and resource-efficient way and then license them to global pharma companies during the preclinical phase. The company has successfully entered into several license agreements amounting to a potential value of USD 747 million in milestone payments as well as income from royalties on sales. The company is headquartered in Stockholm with laboratories in Huddinge. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and is traded under the short name SPRINT. Further information is available on the company's website; www.sprintbioscience.com.
Certified Advisor is FNCA Sweden AB; +46 (0) 8 528 00 399, info@fnca.se, www.fnca.se.

Attachments

Sprint Bioscience presents preclinical VPS34 data at AACR 2022 Annual Meeting

© Modular Finance, source Nordic Press Releases